Resistance of pathogens causing urinary tract infections in children
pdf

Keywords

urinary tract infection
children
microbial resistance

How to Cite

Lucia TURCAN, Svetlana LATUS and Anastasia CARACAS (2024) “Resistance of pathogens causing urinary tract infections in children ”, One Health & Risk Management , p. 132. Available at: https://journal.ohrm.bba.md/index.php/journal-ohrm-bba-md/article/view/742 (Accessed: 2August2025).

Abstract

Introduction. Urinary tract infections are among the most common bacterial infections in children. Limited data on the pharmacokinetic and pharmacodynamic characteristics of antibacterial drugs in pediatric patients may lead to their excessive and irrational use, resulting in the development of complications. Currently, there is an alarming level of antimicrobial resistance among causative pathogens due to the inappropriate and widespread use of antibacterials. Resistant infections are associated with higher morbidity, mortality, and increased healthcare costs.

The aim of this study was to identify the causative pathogens of urinary tract infections in children and analyze their susceptibility to antibacterial preparations for optimal therapeutic management.

Material and methods. This analytical-retrospective study involved analyzing the results of bacteriological urine examinations in children admitted to the specialized wards of Valentin Ignatenco Children’s Municipal Clinical Hospital in 2022, focusing on the identification of microorganisms and evaluation of susceptibility to antibacterial preparations.

Results. According to the data obtained, 39% positive urocultures were identified in children and the most common pathogen detected was Escherichia coli (43% cases), followed by Staphylococcus epidermidis (40%), Enterococcus (6%), Proteus mirabilis (5.5%), Klebsiella pneumoniae (4.5%), Pseudomonas aeruginosa (1%). Escherichia coli showed resistance to cephalosporins-cefaclor (47%), cefuroxime (51%), ceftazidime (40%), cefoperazone (61%), fluoroquinolones-ciprofloxacin (52%), ofloxacin (62%) and, amoxicillin/clavulanic acid in 42% cases. Staphylococcus epidermidis detected in 39% cases, was resistant to ceftriaxone (33%), ceftazidime (28%), cefuroxime (31%), ciprofloxacin (37%), amoxicillin/clavulanic acid in 53% cases. Enterococcus was resistant to ceftriaxone (32%), cefuroxime (37%), cefaclor (30%), ciprofloxacin (29%), ofloxacin (35%), amoxicillin/clavulanic acid (22%). Klebsiella pneumoniae was resistant to ceftazidime (35%), cefoperazone (27%), ceftriaxon (23%), cefuroxime (31%), cephalexin (27%), ciprofloxacin (38%), ofloxacin (46%), amoxicillin/clavulanic acid (27%), and Pseudomonas aeruginosa was resistant to ceftazidime (27%), ceftriaxon (20%), cefuroxime (40%), cephalexin (27%) ciprofloxacin (47%).

Conclusions. Urinary tract infections in children pose a significant challenge due to the specific features of the pediatric population, including the difficulty in conducting studies, limited therapeutic options, contraindications, variability of causative pathogens, and increased resistance to antibacterial therapy. Escherichia coli was the most commonly detected pathogen, with an elevated rate of resistance to amoxicillin/clavulanic acid and cephalosporins, which are commonly used for the treatment of urinary tract infections in children. Rational selection of antibacterials is essential to ensure effective and safe treatment and to prevent urinary tract infections with multidrug-resistant agents.

pdf

|Views: 115| |pdf Downloads: 47|


pdf
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Downloads

Download data is not yet available.

ANNOUNCEMENT

Starting from July 1, 2025, the article processing fee will be 20 EUR (or the equivalent in MDL at the official exchange rate of the National Bank of Moldova). The publication fee for an accepted article will be 150 EUR (or the equivalent in MDL).

Details here:

Processing Fee
A processing fee of 20 EUR (or the equivalent in MDL) will be charged for articles accepted for scientific review by the editorial committee of the One Health and Risk Management journal.
Note: This fee will only be charged if your article has been technically reviewed and accepted.

Publication Fee
Starting from 01.07.2025, a fee of 150 EUR (or the equivalent in MDL) will be charged for articles accepted for publication.
Additionally, authors will bear the cost of English language editing/translation services if the manuscript requires intervention. The fee is 5 EUR (or the equivalent in MDL) per page edited/translated.
The total cost for English editing/translation services will be communicated by the Editorial Board after the manuscript is accepted for publication.

Payment Details:
Payments should be made in MDL to the bank account opened in the name of the Biosafety and Biosecurity Association of the Republic of Moldova.
The invoice will be issued by the end of the month in which the payment was made.

Organization: Biosafety and Biosecurity Association of the Republic of Moldova
Address: 5C A. Cozmescu Street
Fiscal Code: 1017620004120
Bank Code (SWIFT): AGRNMD2X451
IBAN: MD34AG000000022513622370